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Abstract Parkinson’s disease (PD) is characterized by the de-
generation of dopaminergic (DA) neurons in the substantia
nigra pars compacta (SNpc), resulting in motor and non-
motor dysfunction. Physical exercise improves these symptoms
in PD patients. To explore the molecular mechanisms underly-
ing the beneficial effects of physical exercise, we exposed 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP)-treated
mice to a four-week physical exercise regimen, and subsequent-
ly explored their motor performance and the transcriptome of
multiple PD-linked brain areas. MPTP reduced the number of
DA neurons in the SNpc, whereas physical exercise improved
beam walking, rotarod performance, and motor behavior in the
open field. Further, enrichment analyses of the RNA-
sequencing data revealed that in the MPTP-treated mice phys-
ical exercise predominantly modulated signaling cascades that
are regulated by the top upstream regulators L-DOPA,
RICTOR, CREB1, or bicuculline/dalfampridine, associated
with movement disorders, mitochondrial dysfunction, and
epilepsy-related processes. To elucidate themolecular pathways
underlying these cascades, we integrated the proteins encoded
by the exercise-induced differentially expressed mRNAs for
each of the upstream regulators into a molecular landscape,
for multiple key brain areas. Most notable was the opposite
effect of physical exercise compared to previously reported
effects of L-DOPA on the expression of mRNAs in the SN
and the ventromedial striatum that are involved in—among
other processes—circadian rhythm and signaling involving
DA, neuropeptides, and endocannabinoids. Altogether, our
findings suggest that physical exercise can improvemotor func-
tion in PD and may, at the same time, counteract L-DOPA-
mediated molecular mechanisms. Further, we hypothesize that
physical exercise has the potential to improve non-motor symp-
toms of PD, some of which may be the result of (chronic) L-
DOPA use.
Keywords Parkinson’s disease . Physical exercise . MPTP .
L-DOPA . (Non-)motor function .Molecular landscape
Introduction
Parkinson’s disease (PD) is characterized by the degeneration
of dopaminergic (DA) neurons in the substantia nigra pars
compacta (SNpc). The clinical phenotype encompasses motor
symptoms—including bradykinesia, rigidity, tremor, gait dys-
function, and postural instability—and non-motor symptoms
such as sleeping disturbances, pain, or cognitive deficits that
affect executive functions, attention, mood, and working
memory [1–3]. Levodopa (L-DOPA), a precursor of DA, has
been used since the 1960s to treat PD motor symptoms and is
still considered the gold standard of therapy [4, 5]. In recent
years, physical exercise—including intervention strategies
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such as aerobic exercise (e.g., treadmill exercise, cycling, or
dancing) or strength training (e.g., using a modified fitness
counts program or progressive resistance exercising)—has
been reported to improve DA signaling [6, 7] and motor dys-
function [8–11], including bradykinesia [12, 13], rigidity [14],
and tremor [12]. Physical exercise has also been reported to
improve less dopamine-dependent symptoms involving pos-
tural control such as turning performance [6] and instability
[15], as well as cognitive function [2, 16, 17] in PD patients.
Although these beneficial clinical effects of exercise on PD
symptoms are evident, the underlying molecular mechanisms
are not well understood. A better understanding of these pro-
cesses may ultimately lead to a more efficient treatment of
these symptoms, through directly targeting the underlying
pathways.
Systemic administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in mice results in the loss of
nigrostriatal DA neurons, and is widely used to study the
pathophysiological mechanisms underlying DA neuron de-
generation in PD [18]. Moreover, similar to human PD, phys-
ical exercise improves motor behavior and reduces cognitive
impairment in MPTP-treated mice [19–23]. To our knowl-
edge, in this study, we elucidate for the first time the molecular
pathways underlying the beneficial effects of exercise in PD,
using the MPTP mouse model of PD.
Methods
Animals
Six-month-old male C57BL/6J mice were housed, five to a
cage, with ad libitum access to food and water and at a con-
stant 12/12 h light/dark cycle (lights on between 07:00 and
19:00 h). Room temperature was controlled at 21 °C and
roomswere homogenously lighted by 60 LUXwith controlled
humidity. Following arrival, the mice were acclimatized to
their new housing for 1 week, after which they were randomly
assigned to one of four treatment groups: (1) saline-treated; (2)
saline-treated with physical exercise; (3) MPTP-treated; and
(4) MPTP-treated with physical exercise. MPTP-HCl (Sigma-
Aldrich) dissolved in saline was administered via four intra-
peritoneal injections at 2 h intervals, amounting to a total
administered dose of 70 mg/kg (free-base), which in a dose-
response pilot experiment was found as the highest tolerable
dose, with a survival rate of 75%. The intended concentration
of 80 mg/kg, based on similar previous experiments [7, 24,
25], resulted in a higher toxicity and death rate that could not
be justified. The control mice underwent the same protocol
using saline injections. Mice were allowed to recover from the
injections for 2 weeks. All saline-treated mice survived the
protocol, n = 14 for group (1) and n = 14 for group (2),
whereas, due to MPTP treatment, group (3) and group (4)
eventually consisted of n = 10 and n = 13 mice, respectively.
Physical Exercise
A forced chronic and aerobic physical exercise regimen was
initiated 3 weeks followingMPTP or saline treatment and was
performed daily. Mice ran 30min twice a day during a training
period of 28 consecutive days in individual, horizontal lanes
on a five-lane treadmill (Panlab Harvard Apparatus) at a speed
of 20 cm/s (as used before in comparable experimental setups
[7, 24, 26, 27]). Automated short air puffs were used to stim-
ulate the mice to keep running when drifting too far to the
back of the lane. All mice were able to perform the physical
exercise without any noticeable problems. Mice assigned to
the groups without physical exercise were placed in their
housing cage in the same experimental room, adjacent to the
treadmill.
Behavioral Testing
Behavioral testing commenced 1 week before the physical
exercise regimen started (week 0), and was repeated each
week (similar to comparable experiments by others [7,
28–30]) during the exercise regimen (weeks 1–4): beam walk
on the first, rotarod on the third, and open field on the fifth day
of each week, in each case performed between 08:00 and
13:00 h. Prior to all behavioral tests, the animals of all four
treatment groups were habituated to the experimental room for
1 h. Mice from different treatment groups were tested concur-
rently on the rotarod and in the open field.
Open Field
The mice were placed in a white plexiglass box (50×50×40cm)
and video recorded from above for 30 min using EthoVision
XT 7.0 software (Noldus Information Technology B.V.,
Wageningen, The Netherlands). Afterwards, the parameters
Btotal walking distance^, Btotal movement time^, Bmean
velocity ,^ and Bmean angular velocity^ were calculated by
the software, as described previously [31].
Rotarod
Mice were placed on the rotarod apparatus (IITC Inc.,
Woodland Hills, CA, USA) with a rod diameter of 32 mm
and an increasing speed of 4 to 38 rpm in 300 s. Five mice
were tested simultaneously on the rotarod and their latency to
fall was measured (similar to [7, 30, 32]). On each testing day,
each mouse performed one pre-trial and three trials, each with
a maximum duration of 300 s and with a minimum of 1 h of
rest between the trials. The pre-trial enabled the mice to habit-
uate (again) to the rotarod and was not included in the results.
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For each testing day, the latency times of the three trials were
averaged per mouse.
Beam Walk
We assessed the motor coordination and balance bymeasuring
the ability of the mice to transverse a narrow beam [28, 33].
The mice were placed on a white plasticized iron rod (full
length 80 cm, diameter 10 mm) suspended at 40 cm height
and were trained to cross the beam to their home cage.
Training of the mice occurred on the first day. During the
training, the distance to cross was increased each time they
successfully reached their cage, until they were able to reach
their home cage over the full length of the beam. Each week,
the mice were habituated again to the experimental setup by a
pre-trial, which was followed by three trials in which the time
was recorded how long it took for the mice to cross the full
beam to reach their home cage; inter-trial interval was in all
cases at least 1 h. For each testing day, the times of the three
trials were averaged per mouse.
Immunohistochemistry
We performed immunohistochemistry to establish TH protein
expression [24, 34] in the DL, VM, SNpc, and VTA. Twenty-
four hours following their last exercise training, mice were
sacrificed by cervical dislocation, and brains were dissected
and fixated in 4% paraformaldehyde in PBS solution for 3 h
and subsequently cryoprotected by immersion in 30% sucrose
for 24 h. After cryosectioning, DAB staining was performed
on 20-μm-thick coronal slices, placed on gelatinized glass
slides. For this, the sections were washed with PBS
(3×10min), non-specific sites blocked with blocking buffer
(2.5% normal donkey serum, 2.5% normal goat serum, 1%
BSA, 1% glycine, 0.1% lysine, and 0.4% Triton X-100 in
PBS) for 30 min and incubated with rabbit anti-tyrosine hy-
droxylase (TH, 1:1000; Pel-Freez Biologicals #P40101-0; lot
no. 19335) for 16 h at 4 °C. This was followed by 1 h incu-
bations with biotinylated goat-anti-rabbit (1:200; Jackson
ImmunoResearch; 711-065-152; lot no.117858) and avidin-
biotin-peroxidase complex (A and B 1:800; Vectastain Elite
ABC kit, PK-6100 Standard), with PBS washing steps in be-
tween. To visualize antibody binding, the sections with SNpc
and ventral tegmental areas (VTA) were incubated for 30 min,
and those with dorsolateral striatum (DL) and ventromedial
striatum (VM) areas were incubated for 20 min in a DAB/
H2O2-solution potentiated by ammonium nickel sulfate. The
sections were subsequently dehydrated and cover slipped. For
each mouse, every sixth section throughout the DL, VM,
SNpc, and VTAwas included in the counting procedure, and
for optimal comparison between groups, sections of different
treatment groups were stained concurrently.
Images were captured by a Leica DM6000 B microscope.
TH-positive (TH+) cells were counted in the sections of the
SNpc (−2.54 to −3.88mm to Bregma [35]) and VTA (−2.92 to
−3.88 mm to Bregma [35]), using a 20× magnification. The
number of TH+ cells in each section (both the left and right
side) was counted by a blinded assessor and averaged over the
total number of sections per animal. DA fiber density was
estimated in the DL (1.18 to −0.10 mm to Bregma [35]) and
VM (1.54 to 0.62 mm to Bregma [35]) by quantifying the
optic density (OD) with FIJI [36], using a 5× magnification.
In both areas, the OD per section was determined by averag-
ing the OD of ten separate areas within the striatal matrix (i.e.,
in-between the striosomes). Subsequently, the OD was nor-
malized by subtracting the OD of the corpus callosum (CC)
or anterior commissure (AC) for the DL and VM respective-
ly, in the same section, and all sections were averaged per
animal.
RNA Isolation and Sample Preparation
Twenty-four hours following the last physical exercise train-
ing, brains of 8–10 mice per group—that were sacrificed by
cervical dislocation—were dissected, immediately frozen on
dry ice, and stored at −80 °C until further preparation. Specific
brain areas, i.e., prefrontal cortex (PFC), DL, VM, VTA, SN,
and pedunculopontine nucleus (PPN), were then cryopunched
based on the stereotaxic atlas of the mouse brain [35] from
200-μm-thick coronal slices, using punch needles with a di-
ameter of 0.5 and 0.75 mm (see Online Resource 1 for the
estimated punching locations per area). All specimens were
kept at −20 °C during processing. For RNA isolation, punched
samples were homogenized with a TissueLyser (Retsch
GmbH) in 800 μL TRIzol reagent and RNA isolation was
performed according to the manufacturer’s instructions
(Invitrogen). Total RNA concentration was determined with
a NanodropTM ND-1000 spectrophotometer (Thermo Fisher
Scientific Inc.), and RNA quality was visually assessed by 1%
agarose gel electrophoresis. Genomic DNA was removed by
treatment with DNase I in the presence of RNAsin (Thermo
Fisher) in 5× FSB buffer and RNAse-free water.
Subsequently, total RNA samples were stored at −80 °C until
further use. For each treatment group and brain area, RNA
samples of six mice were pooled for RNAseq analysis.
RNA Sequencing and Data Processing
All RNA samples were subjected to RNA sequencing
(RNAseq; HudsonAlpha Genomic Services Lab, Huntsville,
AL) as performed before [37]. In short, total RNA concentra-
tion was estimated by Qubit 2.0 Fluorometer (Invitrogen,
Carlsbad, CA, USA) and RNA integrity by using the
Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad,
CA, USA). RNAseq l ibrar ies were formed from
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approximately 500 ng total RNA of each pooled sample,
followed by poly(A) enrichment. RNAseq was performed
using paired-end sequencing on Illumina HiSeqH2000
(Illumina, San Diego, CA, USA), at 50 base pairs, generating
over 25 million paired reads per sample. Raw RNAseq
FASTQ files were demultiplexed by bcl2fastq conversion
software v1.8.3 (Illumina, Inc., San Diego, CA, USA) using
default settings.
RNAseq data was analyzed using GeneSifter software
(VizX Labs, Seattle, WA). RNAseq reads were mapped to
the Mus musculus reference genome build 37.2, and for this,
the reads were trimmed by 15 base pairs at the five-prime end.
Subsequently, transcript abundance was calculated by estimat-
ing the reads per kilobase of exon per million mapped reads
(RPKM), and normalization to the number of mapped reads
was used for comparison of two mRNA sets. A t test was used
for pairwise comparison and a likelihood ratio test to adjust for
distribution probability.
qPCR Validation
The RNAseq results were validated by comparing expres-
sion levels of at least eight mRNAs/genes per area with
their expression as established by qPCR. These genes
were chosen randomly, although there was one require-
ment, namely that genes from all three comparisons of
interest, i.e., the comparisons to assess the effect of
MPTP (group 3 vs. group 1), physical exercise (group 2
vs. group 1), and physical exercise in the MPTP model of
PD (group 4 vs. group 3), should be included. RNA from
the same samples used for the RNAseq pools was reverse-
transcribed to cDNA with random primers using the
RevertAid H Minus First Strand cDNA Synthesis Kit
(Thermo Scientific, #K1632 lot no 00167909) according
to the manufacturer’s protocol. Three-step qPCR (95 °C
for 10 min, followed by 45 three-step cycles of 95 °C for
5 s, 65 °C for 10 s, and 72 °C for 20 s, and the generation
of melting curves from 70 °C to 95 °C; Rotor-Gene 6000
Series, Corbett Life Science Pty. Ltd.) was performed
using the 2× SensiFAST SYBR No-ROX mix (Bioline
lot no SF582-313209) and primers designed with NCBI
Primer-Blast (www.ncbi.nlm.nih.gov/tools/primerblast/)
a n d s y n t h e s i z e d a t S i g m a L i f e S c i e n c e s
(The Netherlands) (For a complete overview of used
primers, see Online Resource 10, Supp. Table 1). The
housekeeping genes ACTB and YWHAZ were used as
reference for normalization of gene expression. Based on
the qPCR results, the minimum requirements to be includ-
ed in the enrichment analysis—regarding fold change
(FC) cut-off, maximum likelihood ratio value, and mini-
mal RPKM value—were adjusted so that at least 90% of
the expression changes could be validated by qPCR. As
there was insufficient remaining RNA available to
perform the complete qPCR validation for the PPN
RNAseq data, the same cut-off values were used as for
the other brain areas.
Overlap of MPTP- and Exercise-Regulated Genes
To determine the direct effect of exercise on MPTP-regulated
genes, we looked at the overlap between the genes regulated
by MPTP (group 3 vs. group 1) and the genes regulated by
exercise in the MPTP model (group 4 vs. group 3). To quan-
tify this overlap, we used the hypergeometric distribution test
[38]:
p xj n;M ;Nð Þ ¼
M
x
 
N−M
n−x
 
N
n
 
and determined the chance of observing exactly x overlapping
genes from a total of n differentially expressed genes by exer-
cise in the MPTP model, with a total of M genes that were
differentially expressed by MPTP and a total of N genes de-
tected with RNAseq. The number of unique genes detected
with RNAseq in each brain area (N), consists of genes detect-
ed in both comparisons (group 3 vs. group 1 and group 4 vs.
group 3), irrespective of their FC or expression p value. Of
note, for all comparisons only protein-coding genes were
considered.
Enrichment Analysis and Building of Molecular
Landscapes
The Ingenuity pathway analysis software package (www.
ingenuity.com) was used to identify enriched categories in
the lists of differentially expressed protein-coding
mRNAs in each of the brain areas [39]. Again, we fo-
cused on the three main comparisons of interest (see
above)—i.e., the comparisons that assess the effect of
MPTP, physical exercise, and physical exercise in the
MPTP model of PD—in the six brain areas. Ingenuity
assigns genes or rather their corresponding mRNAs/
proteins to functional (sub)-categories, i.e., Bcanonical
pathways^ and Bbiofunctions^, with the latter including
Bdiseases and disorders^ and Bmolecular and cellular
functions^. In addition, Ingenuity generates a list of
Bupstream regulators^, i.e., proteins or compounds that
regulate multiple proteins/mRNAs from the input list.
When possible, the program also calculates a z score that
is based on the expression changes of the input mRNAs
and that is a measure for the directionality of the upstream
regulator, canonical pathway, or biofunction. A z score
< −2 or > 2 is considered significant. For all analyses,
only functional categories and upstream regulators with
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significant enrichment (i.e., Benjamini-Hochberg
corrected p < 0.05) and containing at least two genes were
taken into account.
Proteins/mRNAs regulated by the top upstream regula-
tors were analyzed in more depth to identify their relation
to physical exercise-induced processes in the MPTP mod-
el of PD (i.e., the comparison of group 4 with group 3).
Guided by the results of the Ingenuity enrichment analy-
ses, an extensive literature search was performed for the
(putative) roles of all proteins encoded by the differential-
ly expressed mRNAs as well as their functional interac-
tions, using the UniProt Protein Knowledge Base (http://
www.uniprot.org) and PubMed (http://www.ncbi.nlm.nih.
gov/pubmed). Based on these findings and applying an
approach similar to the one we used previously for
genome-wide association and expression data [39–42],
we then built molecular landscapes containing interacting
proteins encoded by the mRNAs that are differentially
expressed by physical exercise and are known to be reg-
ulated by the top regulators for each brain area. To com-
plement these protein interaction cascades, we added a
number of proteins that were not encoded by the differen-
tially expressed mRNAs but that have been implicated in
PD etiology through other lines of (genetic) evidence. In
this respect, proteins encoded by familial PD candidate
genes were included if they have at least one functional
interaction with one or more other landscape proteins.
Additional proteins were included when having at least
two interactions with other landscape proteins. The mo-
lecular landscapes were drawn with Serif DrawPlus 4.0.
Statistics
Statistical comparisons of values between multiple treatment
groups were carried out using a two-way ANOVA. For behav-
ioral test data, with data at multiple time points, a linear mixed
model was applied using SPSS (IBM, version 23), with
Bweek^, Bphysical exercise^, and BMPTP^ as fixed factors
to calculate the main effects of the training period, physical
exercise, and the interaction between physical exercise and
MPTP. The main effect of MPTP in the behavioral tests was
assessed using a pairwise comparison of saline-treated and
MPTP-treated mice before the start of the exercise regimen.
For pairwise comparison, an F test was used to determine if
the distributions of the compared two groups have the same
variance. Based on the F test, a Student’s t test for equal or
unequal variance was then used to evaluate the significance of
the expression differences. For all comparisons, data are rep-
resented as mean with the standard error of the mean (SEM),
and a p value < 0.05 was considered statistically significant.
The p values calculated with the hypergeometric distribu-
tion test were adjusted for multiple testing using the
Bonferroni correction.
Results
In this study, we assessed the effects of physical exercise in the
MPTP-treated mouse model of PD at the behavioral and mo-
lecular levels.
Fig. 1 Effect of MPTP. Results of the behavioral tests in week 0 (set as
the baseline (100%) for the effect of physical exercise, which is shown in
Fig. 2). No effect of MPTP was shown for the beam walk (a), or rotarod
(b) tests, but MPTP significantly affects the parameters in the open field
(c–f). **p < 0.01; ***p < 0.005, mean + SEM, n = 28 for controls (saline-
treated), and n = 23 for MPTP-treated mice
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Physical Exercise Affects the Motor Function
of MPTP-Treated Mice
At baseline, i.e., following recovery fromMPTP treatment but
before the exercise regimen started, MPTP-treated mice
showed an increased total walking distance (p < 0.01), total
movement time (p < 0.005), and mean velocity (p < 0.005),
and a decreased mean angular velocity (p < 0.005) in the open
field compared to saline-treated control mice. In contrast, their
performance on rotarod and beam walk tests was not signifi-
cantly different from controls (Fig. 1).
In Fig. 2, the effects of physical exercise during the course of
the training period relative to baseline are shown for each of the
four treatment groups. The beam walk task showed a clear
training effect over time in all groups (main effect of Bweek^
p < 0.001), and the test performance was improved by physical
exercise in both the MPTP-treated and saline-treated mice,
without significant differences between the groups (main effect
of physical exercise p < 0.05) and no significant interaction
between physical exercise and MPTP treatment (Fig. 2a).
Rotarod performance was also significantly improved by phys-
ical exercise (p < 0.01), but no improvement over time or inter-
action with MPTP treatment was found (Fig. 2b). Of the tested
parameters in the open field (total walking distance, total move-
ment time, mean velocity, andmean angular velocity), themean
angular velocity was increased (p < 0.001), and the total move-
ment time showed a decreasing trend (p = 0.051) for all treat-
ment groups over time during the exercise regimen (i.e., main
effect of Bweek^). There was no significant (main) effect of
physical exercise on any of the four tested open field parame-
ters, only a trend towards a higher Bmean velocity^ (p = 0.082).
However, for all four open field parameters, significant
Fig. 2 Effect of physical exercise
and interaction with MPTP
compared to the baseline (week
0); results of the behavioral tests
in week 0–4. Measurements in
week 1–4 were normalized to
week 0 (100%). Dark-orange ar-
rows indicate the main effect of
physical exercise (a, b), and light
orange arrows show the effect of
the interaction between physical
exercise and MPTP treatment (c–
f) mean ± SEM n = 14 for both
CNR and CR, n = 10 for MNR
and n = 13 for MR. CNR, control
not running; CR control running,
MNRMPTP-treated but not run-
ning, MRMPTP-treated and
running
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interactions between physical exercise and MPTP treatment
were found (p < 0.05). Physical exercise increased the walking
distance and mean velocity of saline-treated mice, but not of
MPTP-treated mice. Moreover, physical exercise increased the
total movement time of saline-treated mice and decreased that
of MPTP-treated mice. This opposite effect was also observed
for mean angular velocity, i.e., a decrease by physical exercise
in saline-treated mice and an increase in MPTP-treated mice
(Fig. 2c–f).
TH Depletion in the SNpc and Striatum Following MPTP
Treatment
The number of DA neurons in the SNpc and VTA of each
treatment group, as well as an estimate of DA fiber density in
striatal target areas (DL and VM, respectively) was deter-
mined by immunohistochemistry for TH—the rate-limiting
enzyme in DA synthesis. These measures were primarily tak-
en to confirm and estimate the degree of neuronal loss due to
MPTP treatment, but they may also provide some insight into
whether exercise could affect these structural changes. MPTP
significantly reduced the number of TH+ cells in the SNpc
(p < 0.005), but not in the VTA. Pairwise comparison between
the treatment groups revealed that the number of TH+ cells in
the SNpc of MPTP-treated mice without and with physical
exercise was reduced by 29 and 20%, respectively, compared
to the saline-treated group without exercise (both p < 0.05;
Fig. 3). There was no significant effect of physical exercise
on the number of TH+ cells in either the SNpc or the VTA,
and no interaction between MPTP and physical exercise.
In Online Resource 2, the relative OD of TH+ fibers in the
DL, the primary striatal target area of the SNpc, is shown. The
OD of TH+ fibers was reduced byMPTP (p < 0.05), without a
main effect of physical exercise or an interaction between
MPTP and physical exercise. Pairwise comparison showed
that MPTP decreased the density of TH+ fibers in MPTP-
treated mice without exercise by 33% (p < 0.005) compared
to saline-treated mice without physical exercise. There was a
trend towards an increased TH+ OD by physical exercise in
MPTP-treated mice, but this increase was not significant.
Online Resource 3 shows the OD of TH+ fibers in the
VM, the primary striatal target area of the VTA. Although
all treatment groups (physical exercise, MPTP, and MPTP
+ physical exercise) showed a reduced OD of TH+ fibers,
Fig. 3 TH+ neurons in the SNpc
and VTA. The upper panel shows
a representative picture for each
of the four treatment groups and
the lower panel shows the average
number of TH+ neurons in the
SNpc and the VTA per treatment
group. *p < 0.05, mean + SEM,
n = 5 for CNR and MR and n = 4
for CR, and MNR for both brain
areas. CNR control not running,
CR control running,MNRMPTP-
treated but not running, MR
MPTP-treated and running, SNpc
substantia nigra pars compacta,
VTA ventral tegmental area
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no significant effects of MPTP, physical exercise, or their
interaction were found.
qPCR Validation of the RNAseq Data
The RNAseq data were obtained from pooled samples, and in
order to validate these data, the mRNA expression levels in
each of the investigated brain areas were determined in indi-
vidual samples by qPCR. The results of the qPCR experi-
ments (Online Resource 4) led us to adopt the following re-
quirements for the inclusion of differentially expressed
protein-coding mRNAs in the subsequent analyses: FC
> 1.2, likelihood ratio < 0.05, RPKM > 5.
A Direct Effect of Physical Exercise on MPTP-Regulated
Genes
The overlap between the protein-coding mRNAs that are dif-
ferentially expressed due to MPTP alone and due to exercise
in MPTP-treated mice is represented in Online Resource 5. In
all brain areas, the probability of this overlap was calculated
by using the hypergeometric distribution test, which showed
that for all areas, the overlap is greater than would be expected
based on random gene selection (p < 0.05). Further, in all
areas, 82–99% of the overlapping mRNAs are regulated in
opposite directions by MPTP and exercise. Enrichment anal-
yses of mRNAs that overlap but are regulated in opposite
directions are summarized in Online Resource 10, Supp.
Table 2. The VTA and PFC show the most significant results,
and are also the brain areas with the biggest absolute and
relative overlap (i.e., the overlap in number and proportion
of mRNAs). The analysis of the VTA displays a downregulation
of the top regulator Binosine^, whereas the PFC and to a lesser
extent also the DL show an increase in effect of dalfampridine
and bicuculline.
RNAseq Data Analysis: Enriched Regulators, Pathways,
and Biofunctions
Enrichment analysis of the differentially expressed mRNAs
was performed for each of the brain areas examined to inves-
tigate the effects of MPTP (i.e., comparing the MPTP-treated
group without exercise to the saline-treated mice without ex-
ercise), physical exercise (i.e., comparing saline-treated mice
with exercise to saline-treated mice without exercise), and the
effects of physical exercise in MPTP-treated mice (i.e., com-
paring the MPTP-treated mice with exercise to MPTP-treated
mice without exercise). In Tables 1, 2, and 3, a short overview
of the main effects—the top regulator(s), canonical path-
way(s), and biofunction(s)—of MPTP, physical exercise,
and physical exercise in MPTP-treated mice is provided for
each brain area separately. Amore elaborate overview of these
enrichment analyses per brain area can be found in Online
Resource 10, Supp. Tables 3–8.
In all brain areas examined, MPTP treatment affected a set
of mRNAs that is involved in epilepsy, which is reflected by
the presence of the epilepsy-regulating transcription factor
CREB1, the convulsants bicuculline and dalfampridine, and
the biofunction Bepilepsy .^ Other regulators and related func-
tional themes enriched within the mRNAs affected by MPTP
are RICTOR and its regulation of ribosomal and mitochondri-
al proteins, as well as L-DOPA and DA receptor signaling
(Table 1). Of note, in line with the MPTP-mediated decrease
in TH expression in the DL and VM (not significant; see
above), L-DOPA is a significant upstream regulator in both
the DL (p = 2.85E-06; z = −2.635) and the VM (p = 9.97E-04;
z = −1.234), but was not among the top 10 upstream regulators
and is therefore not included in the (Supplementary) Tables.
Furthermore, in the various brain areas examined,
physical exercise affected sets of mRNAs that are reg-
ulated by the upstream regulators CREB1, RICTOR, L-
Table 1 Main effects of MPTP (MPTP-treated mice without physical exercise vs. saline-treated mice without physical exercise) per brain area
For each of the eﬀects, the corresponding z-score, a predicted direcon of the eﬀect, is displayed as increased (z-score ≥ 2; ),
no signiﬁcantly predicted direcon (=) or decreased (z-score ≤ -2; V). “N/A”: no signiﬁcantly enriched canonical pathways or 
biofunc ons for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofuncon(s)
SN CREB1 Neuropathic pain signaling V Seizures
Cognion V
VTA CREB1
RICTOR V
V
V
Protein synthesis Movement disorder =
DL bicuculline/dalfampridine
RICTOR
V
V
Mitochondrial dysfuncon
Protein synthesis
= Epilepsy =
VM CREB1
bicuculline/dalfampridine
=
V
N/A Epilepsy =
PFC bicuculline/dalfampridine V N/A N/A
PPN L-DOPA = Dopamine receptor signaling = Epilepsy
Cognion
=
V
V
V
V
V
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DOPA, and dexamethasone. These regulators overlap to
some extent with the upstream regulators for the MPTP-
regulated mRNAs as mentioned above. However, the
top canonical pathways and biofunctions due to physical
exercise are not epilepsy-related, but rather associated
with Bmitochondrial dysfunction^ and Bmovement
disorder^ (Table 2).
The top regulators of the mRNAs differentially expressed
due to physical exercise in MPTP-treated mice are L-DOPA,
RICTOR, bicuculline/dalfampridine, and CREB1. The top
canonical pathways and biofunctions enriched in exercised
MPTP-treated mice are Bmitochondrial dysfunction^ and
Bprotein synthesis^ in the VTA and DL, BG-protein
signaling^, Bmovement disorder^, Bseizures and cytoskeleton
dynamics^ in the VM and are related to (cell) death in the PFC
(Table 3).
Of note, the predicted direction of effect of the top regula-
tors RICTOR and L-DOPA is changed in the VTA, DL, and
VM of exercised MPTP-treated mice compared to exercised
saline-treated mice. More specifically, the predicted direction
of effect of RICTOR is (strongly) decreased in the VTA and
DL after exercise in saline-treated mice, but is strongly
increased and has no significant predicted direction in the
VTA and DL of exercised MPTP-treated mice, respectively.
Table 3 Main effects of physical exercise in MPTP-treated mice (MPTP-treated mice with physical exercise vs. MPTP-treated mice without physical
exercise) per brain area
For each of the eﬀects, the corresponding z-score, a predicted direc on of the eﬀect, is displayed as very much increased
(z-score ≥ 6; ), increased (z-score ≥ 2; ), no signiﬁcantly predicted direc on (=), decreased (z-score ≤ -2; V) or very much
decreased (z-score ≤ -6; VV). “N/A”: no signiﬁcantly enriched canonical pathways or biofunc ons for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofunction(s)
SN L-DOPA = N/A N/A
VTA RICTOR Mitochondrial dysfunc on
Protein synthesis
=
=
Mitochondrial dysfunc on =
DL RICTOR = Mitochondrial dysfunc on
Protein synthesis
=
=
Mitochondrial dysfunc on =
VM L-DOPA VV G-protein signaling V
V V
V V
V
V
V
V
Movement disorder
Seizures
Cytoskeleton dynamics
Learning
V
V
PFC bicuculline/dalfampridine RAR Ac on = Cell prolife on / cancer
Epilepsy
(cell) death
=
=
V
PPN CREB1 = N/A N/A
Table 2 Main effects of physical exercise (saline-treated mice with physical exercise vs. saline-treated mice without physical exercise) per brain area
For each of the eﬀects, the corresponding z-score, a predicted direc on of the eﬀect, is displayed as increased (z-score ≥ 2; ),
no signiﬁcantly predicted direc on (=), decreased (z-score ≤ -2; V) or very much decreased (z-score ≤ -6; VV). “N/A”: 
no signiﬁcantly enriched canonical pathways or biofunc ons for a brain area (p≥0.05).
Brain area Regulator(s) Canonical pathway(s) Biofunction(s)
SN CREB1 = Dopamine receptor signaling = Movement disorder
Neurotransmission
V
V
VTA CREB1
RICTOR
=
V
Protein synthesis = Seizures V
DL RICTOR VV Mitochondrial dysfunc on
Protein synthesis
= Mitochondrial dysfunc on =
VM L-DOPA = N/A N/A
PFC Dexamethasone V
V
V
V
N/A Cell prolife on / cancer
Mortality
V
PPN L-DOPA = Axonal guidance signaling = Movement disorder
Development of neurons
=
V
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Further, L-DOPA shows a strongly decreased predicted direc-
tion of effect in the VM of exercised MPTP-treated mice,
whereas this direction of effect was absent after exercise
alone.
The Main Molecular Pathways Regulated by Physical
Exercise
To elucidate the main molecular pathways regulated by phys-
ical exercise in MPTP-treated mice, the mRNA sets regulated
by the top upstream regulators L-DOPA (in the SN and VM,
Online Resource 10, Supp. Tables 9 and 10), RICTOR (in the
DL and VTA, Online Resource 10, Supp. Tables 11 and 12),
bicuculline/dalfampridine (in the PFC, Online Resource 10,
Supp. Table 13), and CREB1 (in the PPN, Online Resource
10, Supp. Table 14) were studied in greater detail and used to
build molecular landscapes for each top upstream regulator in
the various brain areas. Here, we provide a short description of
each of these molecular landscapes. In Online Resource 10, all
landscapes are described in full detail. Of note, in the PPN, L-
DOPA is the top upstream regulator following physical exer-
cise or MPTP treatment, but L-DOPA (p = 1.97E-02; z
score = −1.964), although significant, was not among the top
10 upstream regulators following physical exercise in MPTP-
treated mice.
The molecular landscapes of interacting proteins encoded
by the L-DOPA-regulated mRNAs that are differentially
expressed in the SN and the VM due to physical exercise in
MPTP-treated mice, are shown in Figs. 4 and 5, respectively.
In the SN landscape, G-coupled receptor signaling (involving
the proteins ARRB2 and GRP39), glucose uptake and signal-
ing (SLC2A1), DA signaling (PPP1R1B), and reactive oxy-
gen species (ROS) regulation (HSPB6, FTL, ROMO1) con-
verge on the activation of ERK1/2 (ACKR1, EDNRB,
GPR39, IER3, TP53), apoptotic pathways (CASP3, TP53),
CREB1, and circadian clock regulation (PER1, DBP,
CIART) (Fig. 4). In the VM landscape, the main molecular
pathways are (interneuron-mediated) DA release (involving
the proteins CHAT, DOC2B, SYN1, and TH) and signaling
(DRD2, PPP1R1B), cannabinoid signaling (CNR1, FAAH),
and neuropeptide signaling (PDYN, PENK, TAC1) that sub-
sequently regulate/activate ERK1/2, CREB1, and CCND1
signaling. The latter is a cell cycle regulator that may also be
involved in synaptic plasticity and learning [43] (Fig. 5). Of
note, almost all proteins in this landscape are regulated by
physical exercise and L-DOPA in opposite directions.
The RICTOR-regulated mRNAs that are differentially
expressed in the DL and VTA due to physical exercise in
the MPTP-treated mice encode proteins that are specifical-
ly involved in three cellular systems: the complex I-V of
Fig. 4 Landscape of proteins encoded by the mRNAs regulated by
physical exercise and the upstream regulator L-DOPA in the SN.
mRNAs differentially expressed in the SN due to physical exercise in
MPTP-treated mice are shown in gray. Blue proteins are additional
genes/proteins that are associated with PD through genetic and/or
expression studies, whereas white proteins have no known link with
PD. The direction of effect of physical exercise (measured) and L-
DOPA (from literature) on the expression of these mRNAs is depicted
through colored borders. L-DOPA-activated proteins are shown with pur-
ple writing for the protein name, and familial PD proteins are shown with
a blue border
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the electron transport chain, the 40S and 60S ribosomal
subunits, and the proteasome (see Online Resource 10,
Supp. Tables 11 and 12). These are complexes that regulate
cellular energy, protein translation, and protein degrada-
tion, respectively (Online Resources 6 and 7). Of note,
physical exercise and RICTOR have an opposite effect on
the expression of all differentially expressed mRNAs in the
mitochondrial electron transport chain in the DL, whereas
physical exercise and RICTOR exert the same direction of
effect (i.e., a decreasing effect) on the expression of elec-
tron transport chain mRNAs in the VTA.
In the PFC, 8 out of 9 mRNAs differentially expressed
due to physical exercise in MPTP-treated mice and regu-
lated by bicuculline/dalfampridine have been linked to ep-
ilepsy (Online Resource 10, Supp. Table 13). Immediate-
early gene activation is one of the main processes regulated
by these mRNAs e.g., via the early response genes/proteins
FOS, FOSB, and NR4A1, which in turn are regulated by
insulin and low-density lipoprotein. In Online Resource 8,
an overview of the interactions of the proteins encoded by
these mRNAs and their regulation by bicuculline/
dalfampridine and physical exercise is shown in a molec-
ular landscape.
In the PPN, the proteins encoded by the mRNAs that were
differentially expressed due to physical exercise in MPTP-
treated mice and regulated by CREB1 have only a limited
number of interactions in the built landscape (Online
Resource 9). Nevertheless, a few functional themes such as
vascular remodeling, neuropeptide signaling, lipid metabo-
lism, epilepsy/immediate-early gene regulation, and calcium
signaling were identified, with CREB1 as their central regu-
lator (Online Resource 10, Supp. Table 14).
Discussion
This study aimed to explore the molecular mechanisms under-
lying the beneficial effects of physical exercise onmotor func-
tioning in the MPTP-treated mouse model of PD. After vali-
dation of the model, through demonstrating significant nigral
neuronal loss followingMPTP treatment, the effects of a four-
week physical exercise regimen on motor performance, and
Fig. 5 Landscape of proteins encoded by the mRNAs regulated by
physical exercise and the upstream regulator L-DOPA in the VM.
mRNAs differentially expressed in the VM due to physical exercise in
MPTP-treated mice are shown in gray. Blue proteins are additional genes/
proteins that are associated with PD through genetic and/or expression
studies, whereas white proteins have no known link with PD. The direc-
tion of effect of physical exercise (measured) and L-DOPA (from litera-
ture) on the expression of these mRNAs is depicted through colored
borders. L-DOPA-activated proteins are shown with purple writing for
the protein name, and familial PD proteins are shown with a blue border
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the accompanying molecular changes in multiple brain areas
were assessed using behavioral tests and RNAseq analysis,
respectively. The behavioral tests showed that physical exer-
cise improved beam walk and rotarod performance in both
MPTP-treated and control mice, but had a different and often
opposite effect on the four tested open field parameters in
these groups. Our RNAseq findings demonstrated that physi-
cal exercise in MPTP-treated mice mainly affects the expres-
sion of mRNAs involved in L-DOPA-mediated pathways in
the SN and VM that regulate DA signaling, RICTOR-
mediated pathways in the VTA and DL involved in energy
metabolism and cellular stress [44, 45], and bicuculline/
dalfampridine-mediated pathways in the PFC and CREB1-
mediated pathways in the PPN that are both a measure of
neuronal activity [46, 47]. To further elucidate the specific
molecular mechanisms underlying the effects of physical ex-
ercise in MPTP-treated mice, the differentially expressed
mRNAs regulated by these top regulators were integrated into
molecular landscapes, depicting the main biological processes
and signaling cascades affected.
Our animal model was validated by demonstrating a sig-
nificant nigral DA neuronal loss following MPTP treatment.
The observed moderate neuronal loss in the midbrain due to
MPTP treatment, i.e., a 29% reduction of TH-positive neurons
in the SNpc without a statistical significant loss in the VTA, is
in keeping with earlier studies using a similarMPTP treatment
regimen in 5-month-old mice showing 33% loss in the SNpc
and no significant loss in the VTA [48]. Other studies, on 8–
10-week-old mice, have reported a neuronal loss of 29–45%
[49, 50], but also of more than 50% loss in the SNpc [7, 24,
51]. Differences in level of neurodegeneration [52] and mo-
lecular effects [39] due toMPTP toxicity may be explained by
MPTP dosing, age of the mice, and the duration between
MPTP injection and sacrifice [48, 52]. We used aged (6-
month-old) mice to better model age-dependent processes
such as regulation of anti-oxidants [53], neuroplasticity,
neurogenesis [54, 55], and the immune response in PD [56,
57]. To assess how exercise may boost any neuroplastic mech-
anisms of the injured basal ganglia, the physical exercise re-
gime was performed within the recovery phase of striatal DA
levels as reported in younger MPTP-treated mice [58], but
after the acute neurotoxic (molecular) effects of MPTP [39,
59].We did not find a significant effect of physical exercise on
the number of surviving DA neurons, but noted a trend to-
wards an increased number of TH-positive neurons in the
SNpc and an increased TH-positive fiber density in the DL
and VM in MPTP-treated mice with physical exercise com-
pared to MPTP-treated mice without exercise. From previous
studies, it remains unclear whether physical exercise can pro-
tect against cellular loss in the MPTP-mouse model.
Preservation of SNpc neurons by physical exercise has been
described before [27, 51], but the findings were inconsistent
[7, 22].
Regarding motor function, forced exercise has more effect
than voluntary exercise in both PD patients [60] and mice
[61], and it activates the same brain areas as anti-PD medica-
tion does [62]. In this study, the mice were able to perform the
physical exercise without any noticeable problems, suggesting
that their physical exercise regimen is comparable to the
forced moderate aerobic exercise that has been shown to im-
prove both motor and non-motor functions in PD patients [11,
60, 63, 64]. MPTP treatment alone resulted in an increased
activity in the open field, as reported before [48, 52, 65–67],
but did not affect the performance on beam walk and rotarod.
It should be noted that the training effect on the beam walk as
seen in all four treatment groups, especially in week 1 com-
pared to week 0, may implicate the necessity for more exten-
sive training of the mice before the beam walk task in week 0.
Further, the effects of exercise on the motor performance in-
cluded an improvement on the beam walk and rotarod in both
saline and MPTP-treated groups. However, the effects of
physical exercise on the open field parameters in saline-
treated mice was either absent or opposite in MPTP-treated
animals. These findings suggest that some effects of physical
exercise may be dependent on the Bdisease-state^ (i.e., saline-
orMPTP-treated). It could be argued, however, that the lack of
effect of physical exercise in MPTP-treated mice on total
walking distance and mean velocity (Fig. 2) may be due to
their MPTP-induced hyperactivity (Fig. 1) that could have
limited a further increase in motor performance due to phys-
ical exercise. This hyperactivity has been observed more often
following MPTP treatment [48, 65, 66, 68–70] and may result
from compensatory effects induced by e.g., brain areas of the
mesolimbic pathway (see also below). Furthermore, the oppo-
site effect of exercise on total movement time and mean an-
gular velocity in MPTP-treated mice (Fig. 2) compared to the
effect of MPTP alone (Fig. 1) suggests that physical exercise
counteracts the effect of MPTP. This finding could have im-
portant translational value as axial symptoms in PD—such as
hypokinetic rigidity which is reflected by reduced angular
velocity [71–73]—are notoriously more difficult to treat by
medication than appendicular symptoms.
The RNAseq analysis showed that the level of overlap
between MPTP-regulated genes and physical exercise-
regulated genes differed between the brain areas studied and
was particularly high in the PFC and VTA. These data suggest
that in the PFC and VTA, physical exercise influences the
processes affected by MPTP more directly than in the other
areas in which more indirect mechanisms may prevail.
Nevertheless, in all brain areas examined, the majority of
overlapping genes (82–99%) were regulated in opposite direc-
tions by physical exercise compared to MPTP, suggesting
counteracting effects of physical exercise on MPTP-
regulated mechanisms. For example, the enrichment analysis
of the overlapping genes in the PFC and DL (see Online
Resource 10, Supp. Table 2) shows a predicted activation of
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the top regulators dalfampridine, bicuculline, and CREB1—
indicative for neuronal activation [46, 47]—whereas these are
inactivated by MPTP.
The roles of the PD-related brain areas examined in this
study can be summarized in a simplified basal ganglia circuit-
ry model, wherein PPN, SN, and DL are mainly involved in
motor control, and the VTA, VM, and PFC contribute partic-
ularly to the regulation of (complex) behavior and cognition
(Fig. 6) [74–79]. The top regulators—and to a lesser extent
also the canonical pathways and biofunctions—regulated by
physical exercise in the cognition-associated brain areas of
MPTP-treated mice, showed highly significant predicted di-
rections of effect, whereas these effects were less prominent in
the motor-related areas. This implicates that, although physi-
cal exercise is able to improve motor function (as supported
by the behavioral tests), it may also have strong effects on
cognition and behavior. This is interesting from a therapeutic
point of view, because non-motor symptoms in PD patients—
including cognitive impairment, depression, pain, and sleep
disorders—are usually less responsive to dopamine replace-
ment therapy and therefore treatment options are limited
[80–82]. It remains unclear, however, to what extent these
motor and non-motor features of PD have truly discernible
neuroanatomical or molecular substrates, as effects of changes
in mRNA expression in the Bbehavioral areas^VTA, VM, and
PFC on motor function of our animals cannot be excluded.
For example, a recent paper reported that VTA-specific
knockout of RICTOR inmice may affect cognition and mood,
but also results in hyperactivity in the open field [83]. In ad-
dition, it has been suggested that during exercise, the
mesolimbic pathway (including the VTA and VM) may pro-
vide a compensatory functional activation of the motor loop
[84]. Furthermore, whereas L-DOPA is known to improve
DL-mediated motor symptoms, it may impair VM function
in PD patients [85, 86]. Therefore, exercise may counteract
L-DOPA-mediated pathways in the VM and as such improve
VM functionality, which could in turn result in increased com-
pensatory motor-loop activation. Finally, inhibition of
GABAergic interneurons in the PFC by bicuculline increases
the release of DA in the DL through the glutamatergic
corticostriatal pathway [87–89] and may increase the locomo-
tor activity of mice [88, 90]. This is in line with the reduced
TH expression we observed in the DL and the inactivation of
bicuculline/dalfampridine-regulated pathways in the PFC fol-
lowing MPTP treatment, as predicted on the basis of the
RNAseq analysis. Moreover, we found no significantly re-
duced TH expression in the DL of exercised MPTP-treated
mice that, in contrast to MPTP-treated mice without exercise,
showed a predicted activation of the bicucullin/dalfampridine-
regulated pathways in the PFC.
Almost five decades after its introduction [4], the DA pre-
cursor L-DOPA is still the gold standard for symptomatic
treatment to alleviate the motor symptoms of PD [5]. It should
be noted, however, that chronic high-dose L-DOPA use is
associated with complications such as dyskinesias [91–93].
Moreover, the effects of L-DOPA on non-motor symptoms
in PD are even less predictable and L-DOPA use may even
lead to deterioration of these symptoms, e.g., impaired rever-
sal learning or motor sequence learning deficits [94–101]. It
has been suggested that these adverse cognitive effects of L-
DOPA may be due to a higher L-DOPA demand in the motor
systems compared to cognitive areas, resulting in a relative L-
DOPA overdose in cognitive areas [102–104] e.g., the VM
(see also above). Therefore, novel Badd-on^ treatments that
can enable low-dose L-DOPA use and/or reduce the adverse
effects of (long-term) L-DOPA use are desirable. In this
Fig. 6 Overview of the brain areas analyzed, and the top upstream
regulators, and processes per area. The brain areas are shown in a
simplified model of the basal ganglia circuitry. Green, red, and gray
triangles depict positive (> 2), negative (< −2) or non-significant z scores,
respectively, from the enrichment analyses of the physical exercise-
regulated mRNAs in MPTP-treated mice. DL dorsolateral striatum,
GPe globus pallidus external, GPi globus pallidus internal, PFC prefron-
tal cortex, PPN pedunculopontine nucleus, SNpc substantia nigra pars
compacta, SNr substantia nigra reticularis, STN subthalamic nucleus,
VM ventromedial striatum, VTA ventral tegmental area
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respect, our study suggests that physical exercise is an attrac-
tive add-on treatment for PD, and that exercise combined with
L-DOPA treatment may be more beneficial than treatment of
PD patients with L-DOPA alone [9, 105]. Other findings that
support this hypothesis include the reports indicating that
physical exercise not only improves the motor symptoms of
PD patients [8, 9], but also L-DOPA-induced dyskinesias in
PD patients [106] and animal models [107], and cognitive
function in PD patients [2, 16, 17]. In this light, it is of note
that L-DOPA use may result in alpha-synuclein-induced neu-
roinflammation [108] that very recently has been shown to be
reduced by physical exercise [109–111]. Although the major
pathways regulated in our study are not directly related to
inflammation, L-DOPA-mediated pathways may affect
alpha-synuclein regulation [108], and the RICTOR-regulated
pathways may improve mitochondrial function and protein
turn-over, i.e., processes that have been suggested to reduce
alpha-synuclein-induced neuroinflammation [111].
Considering the above, it is worth noting that our land-
scapes revealed that physical exercise and L-DOPA regulate
similar pathways in the SN and VM—often in an opposite
direction—and that most of these pathways have been linked
to sleeping problems (SN) and cognitive and/or motor
dysfunctioning (VM) in PD. For example, the expression of
clock proteins was affected by physical exercise and L-DOPA
in the SN, a brain region known to be involved in the regula-
tion of REM sleep [112, 113] and causing circadian rhythm
irregularities when damaged byMPTP [114, 115]. Further, the
use of L-DOPA can disturb REM sleep [116] and result in a
delayed sleep onset in PD patients, which suggests an
uncoupling of sleep and circadian regulation [117]. On the
other hand, physical exercise can improve circadian rhythm
regulation [118–120] and may therefore serve as a comple-
mentary therapy to strengthen circadian function in PD, as
suggested earlier [121].
In the VM, both physical exercise and L-DOPA regulate DA,
neuropeptide, and endocannabinoid signaling, but in opposite
directions. L-DOPA treatment results in sustained DA signaling
in the striatum and can disrupt DA and (endo)cannabinoid recep-
tor crosstalk [122, 123]. In contrast, physical exercise may rebal-
ance DA signaling after sustained L-DOPA treatment (by reduc-
ing PPP1R1B activation) [107], attenuates depression-like be-
havior by decreasing the expression of neuropeptides [124] and
activates the endocannabinoid system [125–127]. In turn, the
endocannabinoid system modulates synaptic (DA) transmission
in the striatum of PD patients [128–130], restores homeostasis
following DA depletion [131, 132] and exerts beneficial effects
on cognition, mood, and nociception [126]. Therefore, physical
exercise seems to exert a positive effect on the regulation of DA,
neuropeptide, and endocannabinoid signaling. Moreover, these
three signaling pathways are not only associated with L-DOPA-
induced dyskinesia [133–138], a process that is mainly due to
dysregulation in the DL, but are also involved in regulating VM-
associated cognitive functions and behaviors [124, 139–144],
supporting the notion that the anatomical and neurophysiological
boundaries of the striatal domains regulating control of move-
ment (DL) and (more) cognition-related processes (VM) may
functionally overlap [145, 146].
In summary, the molecular pathways that are regulated in
the SN and VMby both physical exercise and L-DOPA can be
directly linked to clinical features of PD. Interestingly, the
overall effects of physical exercise on these pathways seem
to particularly improve the motor and behavioral clinical phe-
notype, whereas (chronic) L-DOPA-treatment can also cause
adverse effects. Moreover, to our knowledge, physical exer-
cise exerts—although it may counteract some L-DOPA-
regulated pathways—no adverse effects on PD patients. To
confirm the positive effects of physical exercise on cognitive
function, future physical exercise studies in PD animal models
and patients should include cognitive tests, e.g., the Y-maze,
the water maze, or reversal learning tasks. Furthermore, these
studies should aim at further elucidating the molecular path-
ways underlying physical exercise in relation to (chronic) L-
DOPA treatment in animal models.
Taken together, our findings provide further evidence that
physical exercise improves motor function in PD, while it also
affects the regulation of non-motor brain areas of MPTP-
treated mice. We found that physical exercise and L-DOPA
exert opposite effects on molecular pathways in several PD-
associated brain areas, including those involved in sleeping
and cognitive function. Overall, the present study suggests
that physical exercise has therapeutic potential, not only to
improve motor function but it may also improve non-motor
symptoms of PD—and perhaps even alleviate detrimental ef-
fects associated with (chronic) L-DOPA use.
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